Article(id=1329837530515616454, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.03.012, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1688400000000, receivedDateStr=2023-07-04, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987574460, onlineDateStr=2026-11-18, pubDate=1710000000000, pubDateStr=2024-03-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987574460, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987574460, creator=13701087609, updateTime=1794987574460, updator=13701087609, issue=Issue{id=1329837471875051704, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='3', pageStart='233', pageEnd='344', issueExtLink='null', onlineDate='null', pubDate='1710000000000', pubDateStr='2024-03-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987560480, creator='13701087609', updateTime=1794988245359, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329840345090732938, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329840345090732939, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=309, endPage=316, ext={EN=ArticleExt(id=1329837530737914567, articleId=1329837530515616454, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Pertuzumab for the treatment of HER2-positive breast cancer: a rapid health technology assessment, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective To perform a rapid health technology assessment (rHTA) on the safety, effectiveness, and economy of pertuzumab in human epidermal growth factor receptor (HER)2-positive breast cancer, and to provide an evidence-based basis for clinical drug decision.
Methods Pubmed, Cochrane Library, Embase, CNKI, Wanfang, official HTA websites were systematically searched. References were screened according to the inclusion and exclusion criterion. And the results were analyzed by data extraction and quality evaluation.
Results 20 systematic review/meta-analysis, 12 economic studies and 4 HTA were included in our study. The results of the study showed that in terms of effectiveness, pertuzumab can improve the pathologic conplete remission (pCR) and objective remission rate (ORR) of trastuzumab, pCR and disease free survival (DFS) of trastuzumab plus chemotherapy for neoadjuvant breast cancer patients. For the patients with metastatic breast cancer, pertuzumab can improve the progression-free survival (PFS) of trastuzumab, PFS, ORR, 1-year, 2-year and median overall survival (OS) of trastuzumab plus taxol, the OS of trastuzumab plus capecitabine. In terms of safety, pertuzumab had mild side effects and good safety. In terms of economy, the combination of pertuzumab was not economical both in abroad and at home.
Conclusion Pertuzumab was effective and safe in the treatment of HER2-positive breast cancer, but the economy was poor.
, authors=Wenjun JI
1, Yangjie SHANG
1, Peng MEN
2, Hui WU
3, Ying MA
1, *, authorsList=Wenjun JI, Yangjie SHANG, Peng MEN, Hui WU, Ying MA, authorCompany=null, correspAuthors=Ying MA, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329837530993767112, articleId=1329837530515616454, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=帕妥珠单抗治疗HER2阳性乳腺癌的快速卫生技术评估, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的 对帕妥珠单抗治疗人表皮生长因子受体(human epidermal growth factor receptor,HER)2阳性乳腺癌的安全性、有效性及经济性进行快速卫生技术评估(health technology assessment,HTA),为临床药物的遴选提供循证依据。
方法 系统检索PubMed、Cochrane Library、Embase、中国知网、万方以及各国HTA官方网站。根据纳入和排除标准筛选文献,经数据提取和质量评价对结果进行描述性分析。
结果 共纳入系统评价/meta分析20篇,经济学研究12篇,HTA4篇。研究结果表明,有效性方面,针对新辅助治疗的乳腺癌患者,帕妥珠单抗可提高曲妥珠单抗的疾病缓解率(pathologic conplete remission,pCR)和客观缓解率(objective remission rate,ORR)、曲妥珠单抗+化疗的pCR和无病生存期(disease free survival,DFS)。针对转移性乳腺癌患者,帕妥珠单抗可提高曲妥珠单抗的无进展生存期(progression free survival,PFS)、曲妥珠单抗+紫杉醇的PFS、ORR、1年、2年和中位生存期(overall survival,OS)以及曲妥珠单抗+卡培他滨的OS。安全性方面,帕妥珠单抗不良反应较轻,安全性较好。经济性方面,无论是国内还是国外,加入帕妥珠单抗均不具有经济性。
结论 帕妥珠单抗治疗HER2阳性乳腺癌的有效性、安全性较好,但经济性较差。
, authors=纪汶君
1, 商杨婕
1, 门鹏
2, 吴慧
3, 马莹
1, *, authorsList=纪汶君, 商杨婕, 门鹏, 吴慧, 马莹, authorCompany=null, correspAuthors=马莹, authorNote=
纪汶君,主管药师,研究方向:内分泌疾病的发病机制、药物临床综合评价。
, correspAuthorsNote=
马莹,主任药师,研究方向:临床药学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=iLbhoxuaBBxGPgBR7Uml5g==, magXml=zRMS4Hy4JxnovWkpkCUXRQ==, pdfUrl=null, pdf=FX/DLWQZZN+lHmFPqiLoOQ==, pdfFileSize=1778238, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=bJpjLtWoKVhTmXhjne7ZWA==, mapNumber=null, fund=null)}, authors=[Author(id=1329837531476112083, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837531543220949, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837531476112083, language=EN, stringName=Wenjun JI, firstName=Wenjun, middleName=null, lastName=JI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837531610329814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837531476112083, language=CN, stringName=纪汶君, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.泰州市人民医院药学部,江苏 泰州 225300, bio={"content":"
纪汶君,主管药师,研究方向:内分泌疾病的发病机制、药物临床综合评价。
"}, bioImg=null, bioContent=
纪汶君,主管药师,研究方向:内分泌疾病的发病机制、药物临床综合评价。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837531211870921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=1., ext=[AuthorCompanyExt(id=1329837531220259530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China), AuthorCompanyExt(id=1329837531228648139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.泰州市人民医院药学部,江苏 泰州 225300)])]), Author(id=1329837531669050072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837531744547546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837531669050072, language=EN, stringName=Yangjie SHANG, firstName=Yangjie, middleName=null, lastName=SHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837531820045019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837531669050072, language=CN, stringName=商杨婕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.泰州市人民医院药学部,江苏 泰州 225300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837531211870921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=1., ext=[AuthorCompanyExt(id=1329837531220259530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China), AuthorCompanyExt(id=1329837531228648139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.泰州市人民医院药学部,江苏 泰州 225300)])]), Author(id=1329837531891348189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837531962651359, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837531891348189, language=EN, stringName=Peng MEN, firstName=Peng, middleName=null, lastName=MEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, address=
2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837532025565920, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837531891348189, language=CN, stringName=门鹏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, address=
2.北京大学医学部药物评价中心,北京 100191, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837531304145612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=2., ext=[AuthorCompanyExt(id=1329837531320922829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531304145612, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China), AuthorCompanyExt(id=1329837531329311438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531304145612, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.北京大学医学部药物评价中心,北京 100191)])]), Author(id=1329837532117840610, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837532214309604, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837532117840610, language=EN, stringName=Hui WU, firstName=Hui, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
3, address=
3.Department of Pharmacy, Yancheng First People's Hospital, Yancheng 224000, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837532285612773, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837532117840610, language=CN, stringName=吴慧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
3, address=
3.盐城市第一人民医院药学部,江苏 盐城 224000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837531396420303, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=3., ext=[AuthorCompanyExt(id=1329837531404808912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531396420303, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.Department of Pharmacy, Yancheng First People's Hospital, Yancheng 224000, Jiangsu Province, China), AuthorCompanyExt(id=1329837531409003217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531396420303, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.盐城市第一人民医院药学部,江苏 盐城 224000)])]), Author(id=1329837532373693159, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329837532440802025, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837532373693159, language=EN, stringName=Ying MA, firstName=Ying, middleName=null, lastName=MA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, *, address=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837532495327978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, authorId=1329837532373693159, language=CN, stringName=马莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, *, address=
1.泰州市人民医院药学部,江苏 泰州 225300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837531211870921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=1., ext=[AuthorCompanyExt(id=1329837531220259530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China), AuthorCompanyExt(id=1329837531228648139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.泰州市人民医院药学部,江苏 泰州 225300)])])], keywords=[Keyword(id=1329837532583408363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=EN, orderNo=1, keyword=pertuzumab), Keyword(id=1329837532679877356, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=EN, orderNo=2, keyword=human epidermal growth factor receptor 2-positive breast cancer), Keyword(id=1329837532793123566, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=EN, orderNo=3, keyword=rapid health technology assessment), Keyword(id=1329837534416319216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=EN, orderNo=4, keyword=effectiveness), Keyword(id=1329837534491816689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=EN, orderNo=5, keyword=safety), Keyword(id=1329837534563119858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=EN, orderNo=6, keyword=economy), Keyword(id=1329837534630228723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=CN, orderNo=1, keyword=帕妥珠单抗), Keyword(id=1329837534701531892, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=CN, orderNo=2, keyword=HER2阳性乳腺癌), Keyword(id=1329837534768640757, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=CN, orderNo=3, keyword=快速卫生技术评估), Keyword(id=1329837534844138230, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=CN, orderNo=4, keyword=有效性), Keyword(id=1329837534902858487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=CN, orderNo=5, keyword=安全性), Keyword(id=1329837534974161656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, language=CN, orderNo=6, keyword=经济性)], refs=[Reference(id=1329837535158711034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[R]. IARC, 2020., articleTitle=null, refAbstract=null), Reference(id=1329837535234208507, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Martinez-sáez O, Pral A. Current and future management of HER2-positive medtastatic breast cancer[J]. Jco Oncol Pract, 2021, 17(10): 594-604., articleTitle=null, refAbstract=null), Reference(id=1329837535284540156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Alvarez RH, Hortobagyi GN. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer[J]. Breast Cancer, 2013, 20(2): 103-110., articleTitle=null, refAbstract=null), Reference(id=1329837535339066109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Von MG, Procter M, De AE,
et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131., articleTitle=null, refAbstract=null), Reference(id=1329837535406174974, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Gianni L, Pienkowski T, Im YH,
et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800., articleTitle=null, refAbstract=null), Reference(id=1329837535477478143, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Swain SM, Baselga J, Kim SB,
et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015, 372(8): 724-734., articleTitle=null, refAbstract=null), Reference(id=1329837535544587008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=O'Sullivan CC, Connolly RM. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer[J]. Oncology (Williston Park), 2014, 28(3): 186-194., articleTitle=null, refAbstract=null), Reference(id=1329837535611695873, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040., articleTitle=null, refAbstract=null), Reference(id=1329837535682999042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Hailey D. Toward transparency in health technology assessment: a checklist for HTA reports[J]. Int J Technol Assess Health Care, 2003, 19(1): 1-7., articleTitle=null, refAbstract=null), Reference(id=1329837535745913603, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Shea BJ, Grimshaw JM, Wells GA,
et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews[J]. Bio Med Central Med Res Methodol, 2007, 7: 10., articleTitle=null, refAbstract=null), Reference(id=1329837535813022469, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Husereau D, Drummond M, Petrou S,
et al. Consolidated health economic evaluation reporting standards (CHEERS) statement[J]. J Med Econ, 2013, 120(6): 765-770., articleTitle=null, refAbstract=null), Reference(id=1329837535875937030, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen S, Liang Y, Feng Z,
et al. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis[J]. Bio Med Central Cancer, 2019, 19(1): 973., articleTitle=null, refAbstract=null), Reference(id=1329837535934657287, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen F, Chen N, Lv Z,
et al. Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis[J]. J Cancer, 2021, 12(6): 1687-1697., articleTitle=null, refAbstract=null), Reference(id=1329837536056292104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Debiasi M, Polanczyk CA, Ziegelmann P,
et al. Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis[J]. Front Oncol, 2018, 8: 156., articleTitle=null, refAbstract=null), Reference(id=1329837536123400969, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang X, Leng J, Zhou Y,
et al. Efficacy and safety of anti-HER2 agents in combination with chemotherapy for metastatic HER2-positive breast cancer patient: a network meta-analysis[J]. Front Oncol. 2021, 11: 731210., articleTitle=null, refAbstract=null), Reference(id=1329837536186315530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Feng F, Zhang T, Yin F,
et al. Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis[J]. Onco Targets Ther, 2019, 12: 959-974., articleTitle=null, refAbstract=null), Reference(id=1329837536257618699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Gunasekara A, Anothaisintawee T, Youngkong S,
et al. Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis[J]. Cancers (Basel), 2022, 14(3): 523., articleTitle=null, refAbstract=null), Reference(id=1329837536324727564, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Hao S, Tian W, Gao B,
et al. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: a meta-analysis of randomized controlled trials[J]. Oncotarget, 2017, 8(12): 19923-19933., articleTitle=null, refAbstract=null), Reference(id=1329837536387642125, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Li X, Wu S, Zhang L,
et al. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials[J]. Ann Transl Med, 2020, 8(24): 1634., articleTitle=null, refAbstract=null), Reference(id=1329837536454750990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Li X, Yao L, Wang M,
et al. Updated bayesian network meta-analysis of adjuvant targeted treatment regimens for early human epidermal growth factor receptor-2 positive breast cancer[J]. J Breast Cancer, 2020, 23(4): 410-429., articleTitle=null, refAbstract=null), Reference(id=1329837536513471247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Liao H, Huang W, Liu Y,
et al. Efficacy and safety of pyrotinib versus T-DM1 in HER2+metastatic breast cancer patients pre-treated with trastuzumab and a taxane: a bayesian network meta-analysis[J]. Front Oncol, 2021, 11: 608781., articleTitle=null, refAbstract=null), Reference(id=1329837536572191505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=刘晨, 杨志光, 路云, 等. 帕妥珠单抗联合曲妥珠单抗治疗HER-2阳性乳腺癌的meta分析[J]. 中国新药杂志, 2019, 28(24): 3035-3041., articleTitle=null, refAbstract=null), Reference(id=1329837536643494674, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=焦苗苗. 双靶联合化疗治疗HER2阳性乳腺癌有效性和安全性的系统评价和meta分析[D]. 长春: 吉林大学, 2020., articleTitle=null, refAbstract=null), Reference(id=1329837536718992147, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang J, Yu Y, Lin Y,
et al. Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis[J]. Ther Adv Med Oncol, 2021, 13: 17588359211006948., articleTitle=null, refAbstract=null), Reference(id=1329837536777712404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Nakashoji A, Hayashida T, Yokoe T,
et al. The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer[J]. Cancer Treat Rev, 2018, 62: 9-17., articleTitle=null, refAbstract=null), Reference(id=1329837536844821269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang C, Chen J, Xu X,
et al. Dual HER2 blockade in neoadjuvant treatment of HER2+Breast Cancer: a meta-analysis and review[J]. Technol Cancer Res Treat, 2020, 19: 1533033820960721., articleTitle=null, refAbstract=null), Reference(id=1329837536907735830, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu D, Chen T, Jiang H,
et al. Comparative efficacy and tolerability of neoadjuvant immunotherapy regimens for patients with HER2-positive breast cancer: a network meta-analysis[J]. J Oncol, 2019, 2019: 3406972., articleTitle=null, refAbstract=null), Reference(id=1329837536962261783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Xie B J, Zhu LN, Ma C,
et al. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer[J]. Breast Cancer, 2020, 27(2): 186-196., articleTitle=null, refAbstract=null), Reference(id=1329837537037759256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu Q, Zhu Z, Liu Y,
et al. Efficacy and safety of HER2-targeted agents for breast cancer with HER2-overexpression: a network meta-analysis[J]. PLoS One, 2015, 10(5): e0127404., articleTitle=null, refAbstract=null), Reference(id=1329837537109062425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu L, Fu F, Li J,
et al. Dual HER2 blockade versus a single agent in trastuzumab-containing regimens for HER2-positive early breast cancer: a systematic review and meta-analysis of randomized controlled trials[J]. J Oncol, 2020, 2020: 5169278., articleTitle=null, refAbstract=null), Reference(id=1329837537167782682, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=张姮. 曲妥珠单抗联合帕妥珠单抗双靶治疗在HER2阳性乳腺癌新辅助治疗中的疗效和安全性meta分析[D]. 福州: 福建医科大学, 2020., articleTitle=null, refAbstract=null), Reference(id=1329837537230697243, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=贾才凤, 张森, 徐浩, 等. 帕妥珠单抗联合曲妥珠单抗、多西他赛一线治疗HER2阳性转移性乳腺癌的成本-效用分析[J]. 中国药房, 2022, 33(4): 481-486., articleTitle=null, refAbstract=null), Reference(id=1329837538828727068, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheng L J, Loke L, Lim E H,
et al. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore[J]. Expert Rev Pharmacoecon Outcomes Res, 2021, 21(3): 449-456., articleTitle=null, refAbstract=null), Reference(id=1329837538912613149, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Moriwaki K, Uechi S, Fujiwara T,
et al. Economic evaluation of first-line pertuzumab therapy in patients with HER2-positive metastatic breast cancer in Japan[J]. Pharmacoecon Open, 2021, 5(3): 437-447., articleTitle=null, refAbstract=null), Reference(id=1329837538971333406, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Diaby V, Ali AA, Williams KJ,
et al. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives[J]. Breast Cancer Res Treat, 2017, 166(3): 951-963., articleTitle=null, refAbstract=null), Reference(id=1329837539038442271, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Diaby V, Alqhtani H, Van BWS,
et al. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan[J]. Breast, 2020, 49: 141-148., articleTitle=null, refAbstract=null), Reference(id=1329837539105551136, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Durkee BY, Qian Y, Pollom EL,
et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2016, 34(9): 902-909., articleTitle=null, refAbstract=null), Reference(id=1329837539197825825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang H, Zhang Y, Huang C,
et al. Cost-effectiveness analysis of trastuzumab emtansine as second-line therapy for HER2-positive breast cancer in china[J]. Clin Drug Investig, 2021, 41(6): 569-577., articleTitle=null, refAbstract=null), Reference(id=1329837539264934690, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Garrison LPJ, Babigumira J, Tournier C,
et al. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States[J]. Value Health, 2019, 22(4): 408-415., articleTitle=null, refAbstract=null), Reference(id=1329837539332043555, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang H, Wang Y, Gong R,
et al. Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China[J]. Ann Palliat Med, 2021, 10(11): 11382-11393., articleTitle=null, refAbstract=null), Reference(id=1329837539390763812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Hassett MJ, Li H, Burstein HJ,
et al. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes[J]. Breast Cancer Res Treat, 2020, 181(1): 43-51., articleTitle=null, refAbstract=null), Reference(id=1329837539449484069, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Jiao B, Garrison LP, JR. The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+metastatic breast cancer[J]. Expert Rev Pharmacoecon Outcomes Res, 2021, 21(3): 497-504., articleTitle=null, refAbstract=null), Reference(id=1329837539529175846, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Leung HWC, Chan ALF, Muo CH,
et al. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer[J]. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(2): 207-213., articleTitle=null, refAbstract=null), Reference(id=1329837539608867623, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Canada CADTH. Pertuzumab (perjeta) for metastatic breast cancer[R/OL]. (2013-08-01) [2023-07-01]. https://www.cadth.ca/perjeta-metastatic-breast-cancer-details., articleTitle=null, refAbstract=null), Reference(id=1329837539701142312, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Canada CADTH. Pertuzumab (perjeta) neoadjuvant breast cancer[R/OL]. (2015-07-16) [2023-07-01]. https://www.cadth.ca/perjeta-or-perjeta-herceptin-combo-pack-neoadjuvant-breast-cancer-details., articleTitle=null, refAbstract=null), Reference(id=1329837539780834089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Canada CADTH. Pertuzumab-trastuzumab for early breast cancer[R/OL]. (2018-12-29) [2023-07-01]. https://www.cadth.ca/perjeta-herceptin-combo-pack-early-breast-cancer-details., articleTitle=null, refAbstract=null), Reference(id=1329837539856331562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Canada CADTH. Pertuzumab (perjeta)[R/OL]. (2022-04) [2023-07-01]. https://www.cadth.ca/pertuzumab., articleTitle=null, refAbstract=null), Reference(id=1329837539915051819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Gradishar WJ, Anderson BO, Abraham J,
et al. Breast cancer, version 3. 2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478., articleTitle=null, refAbstract=null), Reference(id=1329837539977966380, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Giordano SH, Franzoi MAB, Temin S,
et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update[J]. J Clin Oncol, 2022, 40(23): 2612-2635., articleTitle=null, refAbstract=null), Reference(id=1329837540040880941, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心. 帕妥珠单抗注射液生物类似药临床试验指导原则[S/OL]. [2023-07-01]. https://www.cqn.com.cn/ms/att/2021-04/25/cd5d03f3-ff16-4a03-b956-928c34c51dae.pdf., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329837535070630649, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, awardId=Q202049, language=CN, fundingSource=江苏省药学会——天晴医院药学基金(Q202049), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329837531211870921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=1., ext=[AuthorCompanyExt(id=1329837531220259530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.Department of Pharmacy, Taizhou People's Hospital, Taizhou 225300, Jiangsu Province, China), AuthorCompanyExt(id=1329837531228648139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531211870921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.泰州市人民医院药学部,江苏 泰州 225300)]), AuthorCompany(id=1329837531304145612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=2., ext=[AuthorCompanyExt(id=1329837531320922829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531304145612, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China), AuthorCompanyExt(id=1329837531329311438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531304145612, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.北京大学医学部药物评价中心,北京 100191)]), AuthorCompany(id=1329837531396420303, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, xref=3., ext=[AuthorCompanyExt(id=1329837531404808912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531396420303, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.Department of Pharmacy, Yancheng First People's Hospital, Yancheng 224000, Jiangsu Province, China), AuthorCompanyExt(id=1329837531409003217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837530515616454, companyId=1329837531396420303, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.盐城市第一人民医院药学部,江苏 盐城 224000)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.03.012, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.03.012, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.03.012, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.03.012, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1710000000000, fullTextJson=null, articleText=null, reference=null)